BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shaanxi Micot Pharmaceutical Technology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shaanxi Micot Pharmaceutical Tech
 nology's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122401-897@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:MT1013: Phase 3 readout est. (NCT07122401)
DESCRIPTION:MT1013\, phase 3\, Chronic Kidney Disease.\nStudy: Study of MT1
 013 for the Treatment of Patients With Secondary Hyperparathyroidism\nEsti
 mated primary completion: 26 November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mt1013#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07122401
URL:https://assetmemo.bio/drug/mt1013#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
